Show simple item record

dc.contributor.authorGu, M.
dc.contributor.authorIravani, Mahmoud M.
dc.contributor.authorCooper, J.M.
dc.contributor.authorKing, Diane
dc.contributor.authorJenner, P.
dc.contributor.authorSchapira, A. H. V.
dc.date.accessioned2013-06-04T14:00:53Z
dc.date.available2013-06-04T14:00:53Z
dc.date.issued2004-12
dc.identifier.citationGu , M , Iravani , M M , Cooper , J M , King , D , Jenner , P & Schapira , A H V 2004 , ' Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms ' , Journal of Neurochemistry , vol. 91 , no. 5 , pp. 1075-1081 . https://doi.org/10.1111/j.1471-4159.2004.02804.x
dc.identifier.issn0022-3042
dc.identifier.otherPURE: 736807
dc.identifier.otherPURE UUID: 9f60a320-b806-42d6-a371-bd21e4761265
dc.identifier.otherWOS: 000225264700005
dc.identifier.otherScopus: 9744276661
dc.identifier.otherORCID: /0000-0002-4905-9682/work/32997594
dc.identifier.urihttp://hdl.handle.net/2299/10692
dc.description.abstractWe have investigated the ability of pramipexole, a dopamine agonist used in the symptomatic treatment of Parkinson's disease (PD), to protect against cell death induced by 1-methyl-4-phenylpyridinium (MPP+) and rotenone in dopaminergic and non-dopaminergic cells. Pre-incubation with either the active (-)- or inactive (+)-enantiomer forms of pramipexole (10 muM) decreased cell death in response to MPP+ and rotenone in dopaminergic SHSY-5Y cells and in non-dopaminergic JK cells. The protective effect was not prevented by dopamine receptor blockade using sulpiride or clozapine. Protection occurred at concentrations at which pramipexole did not demonstrate antioxidant activity, as shown by the failure to maintain aconitase activity. However, pramipexole reduced caspase-3 activation, decreased the release of cytochrome c and prevented the fall in the mitochondrial membrane potential induced by MPP+ and rotenone. This suggests that pramipexole has anti-apoptotic actions. The results extend the evidence for the neuroprotective effects of pramipexole and indicate that this is not dependent on dopamine receptor occupation or antioxidant activity. Further evaluation is required to determine whether the neuroprotective action of pramipexole is translated to a disease-modifying effect in PD patients.en
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofJournal of Neurochemistry
dc.subjectdopamine agonist
dc.subject1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
dc.subjectneuroprotection
dc.subjectParkinson's disease
dc.subjectpramipexole
dc.subjectSHSY-5Y
dc.subjectPARKINSONS-DISEASE
dc.subjectANTIPARKINSONIAN DRUGS
dc.subjectMETHYLPYRIDINIUM ION
dc.subjectLIPID-PEROXIDATION
dc.subjectDOPAMINE AGONIST
dc.subjectIN-VITRO
dc.subjectLEVODOPA
dc.subject6-HYDROXYDOPAMINE
dc.subjectMICE
dc.subjectTALIPEXOLE
dc.titlePramipexole protects against apoptotic cell death by non-dopaminergic mechanismsen
dc.contributor.institutionDepartment of Human and Environmental Sciences
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionPharmacology and Clinical Science Research
dc.contributor.institutionNeurodegenerative Diseases
dc.contributor.institutionAgriculture, Veterinary and Food Sciences
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dcterms.dateAccepted2004-12
rioxxterms.versionofrecordhttps://doi.org/10.1111/j.1471-4159.2004.02804.x
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record